Self-Injection Feasibility and Acceptability

Subcutaneous DMPA (DMPA-SC, Sayana® Press) is a new, easy-to-use injectable contraceptive that is ideally suited for remote access and even self-injection. This brief provides an overview of PATH’s research studies assessing the feasibility and acceptability of self-injection in Uganda and Senegal. For more information, please visit our Reproductive Health Global Program website.

Publication date: January 2018

Available materials

  1. English

    1. Self-Injection Feasibility and Acceptability 669.1 KB PDF

      Hard copies are not available.

  2. French

    1. Self-Injection Feasibility and Acceptability [French] 674.5 KB PDF

      Hard copies are not available.